My Treatment Approach: HER2-Mutant mNSCLC - Episode 5
Opportunities for HER2 Molecular Testing Education in mNSCLC
Panelists discuss how community oncologists can best serve patients by understanding that lung cancer is no longer 1 disease requiring uniform treatment, emphasizing that comprehensive molecular testing including both next-generation sequencing and immunohistochemistry (IHC) is critical for identifying targetable alterations like HER2 mutations that now have FDA-approved targeted therapies, making broad panel testing essential for optimal patient outcomes in 2025.
Opportunities for HER2 Molecular Testing Education in Metastatic NSCLC
The increasing complexity of treatment options in lung cancer necessitates enhanced educational efforts for community oncologists who manage multiple tumor types and encounter various HER2 implications across different malignancies. The fundamental principle driving comprehensive molecular testing is the shared goal of achieving optimal patient outcomes, which requires moving beyond the historical one-size-fits-all approach of carboplatin and paclitaxel. Modern lung cancer management in 2025 demands recognition that lung cancer represent multiple distinct diseases requiring histology-driven and biomarker-driven treatment strategies, with mutational profiles and expression patterns becoming increasingly important for treatment selection.
Adherence to current National Comprehensive Cancer Network guidelines mandates broad panel next-generation sequencing (NGS) for all lung cancer patients, which simultaneously identifies multiple driver alterations including EGFR, ALK, ROS1, and HER2 mutations. The testing approach must incorporate both tissue-based NGS, despite longer turnaround times, and plasma-based NGS for complementary rapid results. Community oncologists often question the practical value of complex testing, but the availability of FDA-approved targeted therapies for HER2 mutations validates the critical importance of comprehensive molecular profiling. This testing strategy must also include IHC to capture the full spectrum of actionable HER2 alterations.
The clinical imperative extends beyond initial diagnosis to include testing at resistance for patients with targeted mutations who experience progression on targeted therapy. This resistance testing drives identification of future therapeutic opportunities and acquired resistance mechanisms. The evolution of HER2-targeted therapy represents a significant advancement, particularly for HER2 mutations that now have specific targeted treatments available. While the therapeutic implications of HER2 amplifications and overexpression detected by protein levels continue to evolve, the current landscape emphasizes the critical need for universal molecular testing in lung cancer to identify specific gene alterations that can guide personalized treatment approaches.
Related Content:
